2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-W018197
    2-Phenylacetamide 103-81-1 99.92%
    2-Phenylacetamide is a estrogen-like compound that can be isolated from Lepidium apetalum seeds. 2-Phenylacetamide inhibits p38 MAPK signaling pathway, exhibits anti-inflammatory, antioxidant, anti-hypertensive, and anti-fibrosis effects. 2-Phenylacetamide is orally active.
    2-Phenylacetamide
  • HY-W021425
    D-Mannosamine hydrochloride 5505-63-5 ≥98.0%
    D-Mannosamine ((2S,3R,4S,5R)-2-Amino-3,4,5,6-tetrahydroxyhexanal) hydrochloride is a six-carbon amino sugar and an amino derivative of D-mannose. D-Mannosamine hydrochloride can block mannose receptors.
    D-Mannosamine hydrochloride
  • HY-W127711
    Fast Blue B Salt, Dye content ~95% 14263-94-6
    Fast Blue B Salt, Dye content ~95% is a diazo dye, primarily used as a chromogenic substrate in biochemical analysis. Fast Blue B Salt, Dye content ~95% is the coupling agent for the histochemical demonstration of proteases. Fast Blue B Salt, Dye content ~95% can be used for the detection of acid phosphatase in Clostridium perfringens, and also for the determination of lipase activity. Fast Blue B Salt, Dye content ~95% reacts directly with the active hydroxyl groups in phenolic compounds to determine the content of phenolic substances.
    Fast Blue B Salt, Dye content ~95%
  • HY-W587960
    Hercynine 534-30-5 99.96%
    Hercynine (Histidine-betaine) is an intermediate (precursor) and a redox metabolite of Ergothioneine (HY-N1914), which is found in the fine leaf algae, Schizosaccharomyces cerevisiae and honey bees. Hercynine has no effect on scavenging •OH radicals.
    Hercynine
  • HY-Y0337S5
    L-Cysteine-d3 214782-32-8 99.2%
    L-Cysteine-d3 is the deuterium labeled L-Cysteine. L-Cysteine is a conditionally essential amino acid, which acts as a precursor for biologically active molecules such as hydrogen sulphide (H2S), glutathione and taurine. L-Cysteine suppresses ghrelin and reduces appetite in rodents and humans.
    L-Cysteine-d3
  • HY-14657
    Dantrolene sodium 14663-23-1 ≥98.0%
    Dantrolene sodium is an orally active, non-competitive glutathione reductase inhibitor with a Ki of 111.6 μM and an IC50 of 52.3 μM. Dantrolene sodium is also a calcium channel protein inhibitor. Dantrolene sodium inhibits the release of Ca2+ from RyR1 and RyR3, which can be beneficial in a variety of pathologies caused by disruptions in calcium homeostasis (e.g., stroke, ischemia/reperfusion injury, and neurodegenerative diseases). Dantrolene sodium offers relief of muscle spasms, malignant hyperthermia, and antitoxic, antipyretic, and anti-inflammatory properties.
    Dantrolene sodium
  • HY-15259
    CP-640186 591778-68-6 99.21%
    CP-640186 is an orally active and cell-permeable Acetyl-CoA carboxylase (ACC) inhibitor with IC50s of 53 nM and 61 nM for rat liver ACC1 and rat skeletal muscle ACC2 respectively. Acetyl-CoA carboxylase (ACC) is a key enzyme of fatty acid metabolism that enables the synthesis of malonyl-CoA. CP-640186 can also stimulate muscle fatty acid oxidation.
    CP-640186
  • HY-139285
    Arachidonic acid-alkyne 1219038-32-0 ≥99.0%
    Arachidonic acid-alkyne is aω‑alkynyl lipid surrogates for polyunsaturated fatty acid. Arachidonic acid-alkyne has low rates of oxidation. Arachidonic acid-alkyne can be used for tracking the polyunsaturated fatty acids.
    Arachidonic acid-alkyne
  • HY-W068212
    16-Hydroxyhexadecanoic acid 506-13-8 98.0%
    16-Hydroxyhexadecanoic acid (Juniperic acid) is one of the main monomers of cutin in Vicia faba flower petals. 16-Hydroxyhexadecanoic acid can be used as an internal standard for the measurement of hydroxy and hydroperoxy fatty acids in plasma.
    16-Hydroxyhexadecanoic acid
  • HY-100462
    PTP1B-IN-2 1919853-46-5 99.88%
    PTP1B-IN-2 is a potent protein tyrosine phosphatase 1B (PTP1B) inhibitor with an IC50 of 50 nM.
    PTP1B-IN-2
  • HY-14877
    Anagliptin 739366-20-2 99.92%
    Anagliptin (SK-0403) is a highly selective, potent, orally active inhibitor of dipeptidyl peptidase 4 (DPP-4), with an IC50 of 3.8 nM, and less selective at DPP-8 and DDP-9 with IC50s of 68 nM and 60 nM, respectively.
    Anagliptin
  • HY-106443
    Arimoclomol 289893-25-0 99.83%
    Arimoclomol (BRX-220 free base) is an orally active co-inducer of heat shock proteins (HSP). Arimoclomol protects motor neurons by enhancing Hsp expression, thus directly affecting protein aggregation and clearance of misfolded assemblies via the proteasome-ubiquitin system.Arimoclomol can be used for the study of Niemann–Pick disease type C. Arimoclomol can cross the blood-brain barrier and can be used in research on Niemann-Pick disease type C.
    Arimoclomol
  • HY-111455
    LP-211 1052147-86-0 99.87%
    LP-211 is a selective and blood brain barrier penetrant 5-HT7 receptor agonist, with a Ki of 0.58 nM, with high selectivity over 5-HT1A receptor (Ki, 188 nM) and D2 receptor (Ki, 142 nM).
    LP-211
  • HY-124622
    NNC-0640 307986-98-7 98.43%
    NNC-0640 is an effective negative allosteric modulator (NAM) of the human glucagon receptor (GCGR), with an IC50 value of 69.2 nM. NNC-0640 holds potential for research in the field of diabetes.
    NNC-0640
  • HY-160734
    Aleniglipron 2685823-26-9 99.88%
    Aleniglipron (GSBR-1290) is an orally active glucagon-like peptide-1 receptor (GLP-1R) agonist, with an EC50 value of less than 0.1 nM in HDB cell lines in cAMP stimulation assays. Aleniglipron selectively activates the Gαs-cAMP signaling pathway of GLP-1R without β-arrestin recruitment. Aleniglipron induces insulin release, promotes glucose clearance, reduces food intake and decreases body weight. Aleniglipron is applicable to research related to type 2 diabetes and obesity.
    Aleniglipron
  • HY-N0417
    Cucurbitacin E 18444-66-1 99.92%
    Cucurbitacin E is a CDK1 inhibitor that significantly inhibits the activity of the cyclin B1/CDC2 complex. Cucurbitacin E also induces PANoptosis in adrenocortical carcinoma cells in a ZBP1-dependent manner. Cucurbitacin E exhibits synergistic effects with Mitotane (HY-13690); when used in combination, they effectively eliminate tumors.
    Cucurbitacin E
  • HY-108786
    Asfotase alfa 1174277-80-5 98.53%
    Asfotase alfa (ENB-0040) is a bone-targeted genetically engineered glycoprotein. Asfotase alfa increases the survival rate, bone mineralization and bone length and prevents mineralization defects of the feet, rib cage, lower limbs, jaw bones in Akp2 / knockout mice. Asfotase alfa can be used for the research of perinatal, infantile, and juvenile-onset hypophosphatasia (HPP).
    Asfotase alfa
  • HY-144117
    GFB-12811 2775311-17-4 98.04%
    GFB-12811 is a high selective CDK5 inhibitor with an IC50 of 2.3 nM.
    GFB-12811
  • HY-160004
    PXL770 1523493-53-9 99.56%
    PXL770 is an orally active, direct allosteric AMP-activated protein kinase (AMPK) activator. PXL770 decreases C26:0 levels, improves mitochondrial respiration, reduces expression of proinflammatory genes and induces expression of compensatory transporters (ABCD2/3) in ALD fibroblasts/lymphocytes. PXL770 normalizes plasma VLCFA levels, significantly reduces elevated VLCFA levels in brain and spinal cord in Abcd1 KO mice. PXL770 improves glycemia, dyslipidemia, and insulin resistance in ob/ob and high-fat diet (HFD)-fed mice. PXL770 can be used for the study of X-linked adrenoleukodystrophy (ALD), autosomal dominant polycystic kidney disease and nonalcoholic steatohepatitis (NASH).
    PXL770
  • HY-109079A
    Abeprazan hydrochloride 1902954-87-3 99.87%
    Abeprazan hydrochloride (DWP14012 hydrochloride) is a potassium-competitive acid blocker. Abeprazan hydrochloride inhibits H+, K+- ATPase by reversible potassium-competitive ionic binding with no acid activation required. Abeprazan hydrochloride is developed as a potential alternative to proton pump inhibitor for the treatment of acid-related diseases.
    Abeprazan hydrochloride
Cat. No. Product Name / Synonyms Application Reactivity